During the last session, Seres Therapeutics Inc (NASDAQ:MCRB)’s traded shares were 4.17 million, with the beta value of the company hitting 2.03. At the end of the trading day, the stock’s price was $0.73, reflecting an intraday loss of -10.09% or -$0.08. The 52-week high for the MCRB share is $2.05, that puts it down -180.82 from that peak though still a striking 26.03% gain since the share price plummeted to a 52-week low of $0.54. The company’s market capitalization is $124.94M, and the average intraday trading volume over the past 10 days was 4.07 million shares, and the average trade volume was 3.84 million shares over the past three months.

Seres Therapeutics Inc (MCRB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.25. MCRB has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.21.

Seres Therapeutics Inc (NASDAQ:MCRB) trade information

Seres Therapeutics Inc (MCRB) registered a -10.09% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -10.09% in intraday trading to $0.73, hitting a weekly high. The stock’s 5-day price performance is 23.59%, and it has moved by -3.33% in 30 days. Based on these gigs, the overall price performance for the year is -29.97%. The short interest in Seres Therapeutics Inc (NASDAQ:MCRB) is 17.85 million shares and it means that shorts have 5.75 day(s) to cover.

The consensus price target of analysts on Wall Street is $1.25, which implies an increase of 41.6% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1.25 and $1.25 respectively. As a result, MCRB is trading at a discount of -71.23% off the target high and -71.23% off the low.

Seres Therapeutics Inc (MCRB) estimates and forecasts

Statistics show that Seres Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Seres Therapeutics Inc (MCRB) shares have gone down -19.40% during the last six months, with a year-to-date growth rate more than the industry average at 57.30% against 18.00. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 22.47% this quarter and then jump 29.63% in the quarter after that. In the rating firms’ projections, revenue will decrease -100.00% compared to the previous financial year.

Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 12.5M by the end of current fiscal year.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 18.22%. While earnings are projected to return 86.61% in 2024.

MCRB Dividends

Seres Therapeutics Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Seres Therapeutics Inc (NASDAQ:MCRB)’s Major holders

Seres Therapeutics Inc insiders own 13.19% of total outstanding shares while institutional holders control 37.56%, with the float percentage being 43.28%. FLAGSHIP PIONEERING INC. is the largest shareholder of the company, while 91.0 institutions own stock in it. As of 2024-06-30, the company held over 23.12 million shares (or 15.8226% of all shares), a total value of $16.73 million in shares.

The next largest institutional holding, with 22.72 million shares, is of FMR LLC’s that is approximately 15.5489% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $16.44 million.